KZIA · Kazia Therapeutics Limited ADR
United States · RS rating 29 · As of 2026-11-03
| Price | 8.08 USD |
|---|---|
| 1-day change | +0.8% |
| RS rating (overall / 1M / 3M / 12M) | 29 / 29 / 19 / 54 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 19 / 26 / 12 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +52.2% |
| Market cap (USD) | $135.1M |